Exchange Capital Management Inc. Boosts Stock Position in The Clorox Company (NYSE:CLX)

Exchange Capital Management Inc. boosted its stake in shares of The Clorox Company (NYSE:CLXFree Report) by 16.6% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 6,157 shares of the company’s stock after purchasing an additional 878 shares during the period. Exchange Capital Management Inc.’s holdings in Clorox were worth $1,000,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of CLX. Mizuho Securities USA LLC grew its stake in Clorox by 46,877.8% in the 3rd quarter. Mizuho Securities USA LLC now owns 4,500,000 shares of the company’s stock valued at $733,095,000 after acquiring an additional 4,490,421 shares during the period. Ilex Capital Partners UK LLP grew its holdings in shares of Clorox by 512.7% during the 3rd quarter. Ilex Capital Partners UK LLP now owns 542,110 shares of the company’s stock worth $88,315,000 after purchasing an additional 453,624 shares during the period. Assenagon Asset Management S.A. raised its position in Clorox by 302.0% in the fourth quarter. Assenagon Asset Management S.A. now owns 353,367 shares of the company’s stock valued at $57,390,000 after purchasing an additional 265,455 shares during the period. State Street Corp increased its stake in Clorox by 3.1% during the third quarter. State Street Corp now owns 8,182,109 shares of the company’s stock worth $1,332,947,000 after purchasing an additional 245,525 shares during the period. Finally, FMR LLC boosted its holdings in Clorox by 27.6% in the third quarter. FMR LLC now owns 776,232 shares of the company’s stock valued at $126,456,000 after purchasing an additional 168,111 shares during the period. Hedge funds and other institutional investors own 78.53% of the company’s stock.

Analyst Ratings Changes

CLX has been the topic of a number of research analyst reports. TD Cowen upgraded shares of Clorox from a “sell” rating to a “hold” rating and boosted their price objective for the stock from $155.00 to $170.00 in a research report on Wednesday, November 6th. DA Davidson reduced their target price on Clorox from $171.00 to $169.00 and set a “neutral” rating for the company in a report on Wednesday, February 5th. Barclays raised their price target on Clorox from $130.00 to $140.00 and gave the company an “underweight” rating in a research report on Wednesday, February 5th. Wells Fargo & Company lifted their target price on shares of Clorox from $157.00 to $161.00 and gave the stock an “equal weight” rating in a research report on Tuesday, February 4th. Finally, StockNews.com lowered shares of Clorox from a “buy” rating to a “hold” rating in a research report on Sunday, January 5th. Four equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $158.21.

View Our Latest Analysis on Clorox

Clorox Trading Down 1.7 %

Shares of CLX stock opened at $154.52 on Tuesday. The company has a quick ratio of 0.60, a current ratio of 0.94 and a debt-to-equity ratio of 20.52. The business’s 50 day moving average is $157.53 and its two-hundred day moving average is $160.03. The company has a market cap of $19.03 billion, a PE ratio of 42.22, a price-to-earnings-growth ratio of 2.62 and a beta of 0.42. The Clorox Company has a 12 month low of $127.60 and a 12 month high of $171.37.

Clorox (NYSE:CLXGet Free Report) last released its quarterly earnings data on Monday, February 3rd. The company reported $1.55 earnings per share for the quarter, beating analysts’ consensus estimates of $1.39 by $0.16. Clorox had a return on equity of 316.87% and a net margin of 6.38%. During the same quarter in the prior year, the business earned $2.16 EPS. Equities analysts predict that The Clorox Company will post 7.15 EPS for the current year.

Clorox Profile

(Free Report)

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.

Read More

Want to see what other hedge funds are holding CLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Clorox Company (NYSE:CLXFree Report).

Institutional Ownership by Quarter for Clorox (NYSE:CLX)

Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.